Muhammad Alaa Eldeen
Overview
Explore the profile of Muhammad Alaa Eldeen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
241
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Akl M, Eldeen M, Kassem A
AAPS PharmSciTech
. 2024 Aug;
25(6):184.
PMID: 39138693
Transdermal administration techniques have gained popularity due to their advantages over oral and parenteral methods. Noninvasive, self-administered delivery devices improve patient compliance and control drug release. Transdermal delivery devices struggle...
2.
Eid R, Mamdouh F, K Abdulsahib W, Alshaya D, Al-Salmi F, Ali Alghamdi M, et al.
Front Mol Biosci
. 2024 Jun;
11:1387919.
PMID: 38872915
Increased Actin-like 6A (ACTL6A) expression is associated with various cancers, but its comprehensive investigation across different malignancies is lacking. We aimed to analyze ACTL6A as a potential oncogene and therapeutic...
3.
Eid R, Abadi A, Alghamdi M, El-Kott A, Mohamed G, Al-Shraim M, et al.
Toxicon
. 2024 May;
244:107750.
PMID: 38750940
Malathion (MAL) is one of the highly toxic organophosphorus (OP) compounds that induces hepatotoxicity. Echinops. ritro leaves extract (ERLE) is traditionally used in the treatment of bacterial/fungal infections. This study's...
4.
Eldeen M, Mamdouh F, K Abdulsahib W, Eid R, Alhanshani A, Shati A, et al.
Pharmaceuticals (Basel)
. 2024 Feb;
17(2).
PMID: 38399367
Replication Factor C Subunit 4 (RFC4), an oncogene implicated in many human cancers, has yet to be extensively studied in many cancer types to determine its expression patterns and tumor...
5.
Unraveling Extremely Damaging Variants and Their Potential Implications for IRAK4 Inhibitor Efficacy
Behairy M, Eid R, Otifi H, Mohammed H, Alshehri M, Asiri A, et al.
J Pers Med
. 2023 Dec;
13(12).
PMID: 38138875
Interleukin-1-receptor-associated kinase 4 (IRAK4) possesses a crucial function in the toll-like receptor (TLR) signaling pathway, and the dysfunction of this molecule could lead to various infectious and immune-related diseases in...
6.
Zaki M, Eldeen M, K Abdulsahib W, Shati A, Alqahtani Y, Al-Qahtani S, et al.
Diagnostics (Basel)
. 2023 May;
13(9).
PMID: 37175004
Emerging research findings have shown that a centrosomal protein () is a potential oncogene in numerous human malignancies. Nevertheless, no pan-cancer analysis has been conducted to investigate the various aspects...
7.
Soltan M, Eldeen M, Sajer B, Abdelhameed R, Al-Salmi F, Fayad E, et al.
Biology (Basel)
. 2023 Apr;
12(4).
PMID: 37106813
Epithelial cell transforming 2 (ECT2) is a potential oncogene and a number of recent studies have correlated it with the progression of several human cancers. Despite this elevated attention for...
8.
Soltan M, Eldeen M, Eid R, Alyamani N, Alqahtani L, Albogami S, et al.
Front Mol Biosci
. 2023 Apr;
10:1017148.
PMID: 37033447
Several recent studies pointed out that chromodomain-helicase-DNA-binding protein 1-like (CHD1L) is a putative oncogene in many human tumors. However, up to date, there is no pan-cancer analysis performed to study...
9.
Eid R, Eldeen M, Soltan M, Al-Shraim M, Aldehri M, Alqahtani L, et al.
Front Genet
. 2023 Feb;
13:1008502.
PMID: 36726716
: Mammalian WD-repeat protein 12 (WDR12), a family member of proteins containing repeats of tryptophan-aspartic acid (WD), is a potential homolog of yeast Ytm1p and consists of seven repeats of...
10.
Khan S, Rizwan M, Zeb A, Eldeen M, Hassan S, Rehman A, et al.
Vaccines (Basel)
. 2023 Jan;
11(1).
PMID: 36679917
Syphilis, a sexually transmitted infection, is a deadly disease caused by . It is a Gram-negative spirochete that can infect nearly every organ of the human body. It can be...